News
The day at a glance · 2 min read
Mood · Cautious
+10
Sentiment, −100 to +100
ABBV Current Price
$262
Street Target
$279
Potential Total Return
38%
Key driverDrug pricing policy developments and dividend strength driving sector attention as AbbVie introduces 340B rebate program before 2027 Medicare price negotiations
Daily briefHealthcare· Money365.Market AI ·

Pharma Pricing Spotlight Amid Dividend Focus

AbbVie unveils 340B rebate pilot ahead of Vraylar Medicare cut; Gilead and Pfizer draw dividend interest as Moderna extends Q3 rally

Drug Pricing & Medicare Policy

Neutral
ABBV
AbbVie (ABBV) announced its 340B rebate pilot on October 2, with the initiative arriving as the company faces a Medicare price cut for Vraylar in 2027. The stock is trading at $262 with a street target around $279 and a mid-point target near $362, representing potential total return of approximately 38% and an annualized internal rate of return around 8% per year.

Big Pharma Income Strategies

Neutral

GILD Dividend Yield

3.98%
GILDPFE
Gilead Sciences (GILD) passed a high-quality dividend screen with a 3.98% yield, supported by strong profitability metrics and a cheap valuation, though the analysis identified key risks requiring monitoring. The company is attracting attention from dividend-focused investors seeking quality income streams with valuation support.
Pfizer (PFE) and Novo Nordisk are being compared as high-yield dividend stocks, with Novo Nordisk covering its dividend while Pfizer does not, though investors appear increasingly worried about Novo's future. The comparison highlights diverging dividend sustainability profiles among large pharmaceutical companies.

Biotech Performance & Positioning

Bullish

MRNA Q3 Performance

175%+175%
MRNALLY
Moderna (MRNA) ranked as the second top-performing stock in the US market in the third quarter, soaring 175% with the surge primarily driven by positive growth prospects from its combined therapy candidate for treating the most common type of skin cancer. The vaccine maker is set to join the Nasdaq 100 index following the dramatic quarterly performance.
Eli Lilly (LLY) has carved out a strong position in the pharmaceutical industry, with much of its competitive advantage now tied to leadership in diabetes and obesity treatments. The company's moat comes from several factors working together including drug innovation, patent protection, manufacturing capacity, brand strength, and a deep pipeline of new treatments.

Gene Therapy & Life Sciences Tools

Neutral
TMO
Roche faces an FDA decision this week as gene-therapy stocks step into focus, with Rocket, RegenXBio, Precision BioSciences, Kyverna and uniQure scheduled to present at a cell and gene-therapy conference. The presentations highlight increasing attention on the gene therapy sector amid regulatory milestones.
Thermo Fisher (TMO) was added to JPMorgan's October stock picks alongside American Express and Liberty Energy after a mixed September. The addition reflects renewed analyst interest in the life sciences tools sector.

Sector Valuation Comparisons

Neutral
AMGN
Amgen (AMGN) and Vertex Pharmaceuticals are being compared as biotech investment options in 2026, with one offering a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice between the two companies comes down to whether investors prioritize income stability or growth potential.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy